Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Recruiting

• Conditions: Hidradenitis Suppurativa

• Registration Number: NCT04115566
• Lead Sponsor: University of California, San Francisco

Brief Summary

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-09-18
• Study First Submitted QC: 2019-10-01
• Study First Posted: 2019-10-04
• Study Start: 2020-08-01
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-11
• Last Update Posted: 2024-10-16
• Primary Completion: 2030-01-01
• Study Completion: 2030-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

1. Male or female ≥ 10 years of age
2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Read More

Exclusion Criteria

1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary Objective	2019-2029	The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.

Secondary Outcome Measures

Name	Time	Method
Secondary Objective	2019-2029	Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.

Trial Locations

Locations (1)

University of California San Francisco; 🇺🇸 San Francisco, California, United States